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Borges, Ju´lio Ce´sar, Jose´ Antoˆnio Silva, Jr., Maria
Aparecida Gomes, Eliane Sa Lopes Lomez, Katia Mo-
raes Leite, Ronaldo Carvalho Araujo, Michael Bader,
Joa˜o Bosco Pesquero, and Jorge Luiz Pesquero. Tonin
in rat heart with experimental hypertrophy. Am J Physiol
Heart Circ Physiol 284: H2263–H2268, 2003. First published
January 23, 2003; 10.1152/ajpheart.00416.2002.—The
present study was undertaken to determine tonin expression
and activity in rat heart presenting isoproterenol-induced
hypertrophy. Renin, angiotensin-converting enzyme (ACE),
and angiotensinogen (AG) expression were also determined.
Wistar rats were treated with isoproterenol for 7 days (5
mg  kg1  day1 sc). For untreated animals, the levels of
tonin-specific activity in the atrium were 2.6- and 5.5-fold
higher than those of the left and right ventricle, respectively.
After treatment, the levels of tonin-specific activity increased
twofold in the atrium but did not change in the ventricles.
Renin expression was not detectable in these structures, and
ACE expression levels did not change with treatment. AG
expression was detected in the left ventricle at very low levels
compared with the atrium and increased significantly only in
the hypertrophied atrium (1.8-fold). Tonin mRNA was not
detected in the ventricle but was found at low levels in the
atrium, which increased after isoproterenol treatment. Our
results permit us to conclude that tonin may play a role in the
process of heart hypertrophy in the rat.
angiotensin II; isoproterenol; growth myocardium; renin; an-
giotensinogen
CARDIAC HYPERTROPHY is an in vivo adaptive response
that allows the organism to maintain or to increase its
cardiac output. Although the mechanism that triggers
this cardiovascular dysfunction is still unclear, the
involvement of hormones and paracrine substances
related with blood pressure control, such norepineph-
rine and the renin-angiotensin system (RAS), has been
reported (11, 24, 40). Activation of the local RAS by
mechanical stress (32) or -adrenergic stimulation can
provoke hypertrophy (9). The reversion of cardiac hy-
pertrophy after angiotensin-converting enzyme (ACE)
inhibitors and angiotensin II (ANG II) antagonist
treatment (12, 45) suggests that ANG II plays an
important role in the cardiac hypertrophy seen in most
forms of clinical and experimental hypertension. In the
past two decades, a wealth of information has been
amassed about the role of tissue ANG II. In the heart,
this peptide seems to mediate several important func-
tions, such as vascular coronary tonus, positive inotro-
pic and chronotropic effects (38), and also growth of the
myocardium (13, 28). There is evidence that all the
components of the RAS are present in the heart. Even
though some authors speculate on the putative mech-
anism of renin uptake from the plasma into the heart
(14), it is well described that renin synthesis in the
heart is 2% of that of the kidney (15). On the other
hand, some studies have demonstrated that, in the
human heart, ACE inhibitors are able to block only
partially the formation of ANG II and that the major
proteinase responsible for ANG II generation in the left
ventricle (LV) is the serine proteinase chymase (46).
The existence of alternative pathways for ANG II for-
mation involving proteinases other than renin and
ACE has been shown in several species, including
humans (4, 39, 41). An enzyme that represents a good
candidate to be involved in ANG II generation as an
alternative route is the serine proteinase tonin, which
is able to release ANG II directly from angiotensinogen
(AG) (20). Tonin is present in many organs, such as the
brain, kidney, prostate, and submandibular glands (1,
2, 10, 21, 29, 30). There is no information about the
presence of tonin in the rat heart. Tonin is secreted
from the submandibular gland to saliva and venous
effluent by controversial mechanisms. In in vivo exper-
iments, by intraperitoneal injection of the -adrenocep-
tor agonist isoproterenol, it was shown that tonin se-
cretion is enhanced by -adrenergic stimulation (18,
19, 22). On the other hand, experiments using dis-
persed cells from the rat submandibular gland showed
that the release of tonin is -adrenoceptor dependent
(25, 31).
Chronic exposure to isoproterenol can induce cardiac
hypertrophy (34). The myocardium growth induced by
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isoproterenol could be the result of either direct stim-
ulation or mediated by secondary metabolic, hemody-
namic, or endocrine alterations produced by adrenergic
stimulation. In this model, the ANG II-generating sys-
tem(s) is activated, and the progression and prevention
of cardiac hypertrophy were associated with changes in
cardiac tissue ANG II (42). In the present study, with
the use of repeated administration of isoproterenol in
subpressor dosages, we provide evidence for the partic-
ipation of tonin in the development of isoproterenol-
induced cardiac hypertrophy in the rat.
METHODS
Hypertrophy development and tissue extraction. All exper-
imental procedures were conducted in accordance with our
institutional guidelines. Cardiac hypertrophy was induced in
male Wistar rats (n  12) by treatment with isoproterenol
(Sigma) for 7 days (5 mg  kg1  day1 sc). The control group
received saline injections (n  12). On day 8, animals were
killed by decapitation, and the heart was quickly removed,
washed with 0.9% NaCl (wt/vol), and separated into atrial
[right plus left atria (AT)], right ventricular (RV), and LV
sections. Hypertrophy was monitored by a cardiac index
(heart weight/body weight) and by atrial natriuretic peptide
(ANP) expression in the LV of animals. The use of ANP
mRNA measurement to confirm cardiac hypertrophy status
has been used by other groups (5, 42, 47).
Tonin activity. After being weighed, heart structures (n 
9 each) were homogenized in 250 mM sucrose (pH 7.0) con-
taining 20 mM EDTA, 10 mM o-phenanthroline, 16 mM
dipyridyl, and 10 mM sodium tetrathionate for determina-
tion of tonin activity. After centrifugation, a fraction of each
supernatant was incubated with synthetic renin substrate
[(1–14)AG] in 0.1 M sodium phosphate buffer (pH 6.8) con-
taining the inhibitors previously described, and the ANG II
liberated was determined by radioimmunoassay (21). Alter-
natively, tissues were homogenized in sucrose solution with-
out inhibitors and incubated with (1–14)AG also in the ab-
sence of inhibitors.
Gene expression. From a second group of treated (n  3)
and control animals (n  3), the heart structures, subman-
dibular gland, and kidney were used for extraction of total
RNA using TRIzol reagent (Life Technologies; Eggenstein,
Germany) according to the protocol of the manufacturer. Rat
tonin, ANP, AG, renin, ACE, and -actin mRNA were iden-
tified by ribonuclease protection assay (RPA; AMS Biotech-
nology) or RT-PCR. For RPA, the specific probes were gener-
ated using as the template a DNA fragment cloned into the
pGEM-T Easy vector (Promega). The probes were prepared
by linearization of the plasmid and purification from agarose
gel using the QIAEX II gel extraction kit (Qiagen). The
labeled antisense RNA probes were synthesized by T7 RNA
polymerase in the presence of [32P]UTP using a RNA tran-
scription kit (Stratagene) and purified on a 5% acrylamide-
containing 8 M urea gel. Fifty micrograms of total RNA per
sample were hybridized with 32 nCi of the radiolabeled
antisense probe (4). The -actin probe was used as a control
for the amount of RNA. The hybridized fragments protected
from ribonuclease A digestion were separated by electro-
phoresis on a denaturing gel (5% polyacrylamide and 8 M
urea) and analyzed using a FUJIX BAS 2000 phosphorim-
ager system (Fuji). The assays were repeated at least three
times with similar results. The RT reaction was carried out
using 1 g of total RNA, oligo(dT) primers, and the reverse
transcriptase Moloney Murine Leukemia Virus (Life Tech-
nologies), followed by a specific PCR utilizing the primers
ton5 (5-ACCTGATACCATGTGGCTCC-3) and ton3 (5-CAT-
GGTGGGTTTTATTGAGAC-3) for tonin, rACE5 (5-GTCAC-
CGCCGCTCTTGATGCTG-3) and rACE3 (5-GGCTTCAT-
TACTGAGGGCAG-3) for ACE, and A954–7 (5-GTTCCGAT-
GCCCCGAGGATCT-3) and A954–8 (5-GCATTTGCGGTG-
CACGATGGA-3) for rat -actin. -Actin cDNA was ampli-
fied as a control for the amount of RNA.
Other methods. Iodinated ANG II (35) was purified utiliz-
ing a reverse-phase column (Mino RPC) in a HPLC system.
Protein (7) and peptide (26) concentrations were determined
spectrophotometrically [molar extinction coefficient () 
1,379 M1  cm1 for ANG II and   2,758 M1  cm1 for
(1–14)AG]. Data are given as means 	 SD. Statistical com-
parisons were performed by one-way ANOVA and Student’s
t-test for unpaired data to evaluate differences between the




In the present study, treatment with isoproterenol
for 7 days induced significant hypertrophy in the rat
heart. This effect was evaluated by the ratio between
the weight of the heart or heart structures and the
weight of the respective animal (Fig. 1) and by the
expression level of ANP, which is a marker for hyper-
trophy, in the LV (Fig. 2, A and B). The hypertrophic
effect of isoproterenol was observed by the increase in
the heart ratio of the treated animal compared with the
value obtained for the control animal (4.33 	 0.24 vs.
3.25 	 0.23) and for all the heart structures analyzed
separately, however, with different ratios (RV: 1.14 	
0.05 vs. 0.79 	 0.03, LV: 2.79 	 0.15 vs. 2.11 	 0.11,
Fig. 1. Effect of isoproterenol (Iso) treatment on the weight of rat
heart structures. AT, left plus right atrium; RV, right ventricle; LV,
left ventricle. *P 
 0.05 compared with control.
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and AT: 0.24 	 0.01 vs. 0.17 	 0.01). The expression of
ANP in the LV, normalized by the expression of the
housekeeping gene -actin, increased significantly af-
ter treatment (18.62 	 1.38 vs. 10.51 	 0.56).
Figure 3 shows the tonin-specific (A) and total activ-
ities (B) determined in the heart structures. Tonin-
specific activity was significantly higher in the AT
compared with the other structures, and treatment
with isoproterenol significantly increased the specific
activity in this structure (0.91 	 0.09 vs. 0.47 	 0.07)
but not in the RV and LV (Fig. 3A). The level of total
tonin activity was shown to be higher in the LV; how-
ever, only in the AT did it significantly increase after
isoproterenol treatment (0.83 	 0.12 vs. 0.37 	 0.05).
With the use of the RPA, we evaluated tonin expres-
sion levels in the AT and LV structures (Fig. 4) and
compared the values to that of the submandibular
gland. In the untreated group, tonin expression was
undetectable in the heart structures. Isoproterenol
treatment induced tonin expression to levels detectable
only in the AT. Evaluation of mRNA levels for AG in
the AT and LV showed that this gene is expressed in
the AT at higher levels than in the LV (Fig. 5). Isopro-
terenol treatment provoked a significant augmentation
of AG expression only in the AT (1.8-fold). Renin ex-
pression was also evaluated in the heart structures
and compared with the gene expression in the kidney.
In the heart structures, renin is expressed at undetect-
able levels even after isoproterenol-induced hypertro-
phy (Fig. 6). Expression of ACE was determined by
RT-PCR and, for comparison, tonin expression was also
determined by the same method. Isoproterenol treat-
ment did not change the levels of ACE expression in
the AT and LV, and again we verified an increase of
tonin expression in the AT (Fig. 7).
DISCUSSION
The structural basis of cardiac hypertrophy and the
participation of ANG II in this process has been exten-
sively studied, and several experimental data suggest
that the process is dependent on a direct effect of ANG
II on the myocytes (6, 8, 48). Calcineurin, a Ca2/
calmodulin-dependent phosphatase, has a pivotal role
as a cellular target for a variety of Ca2-dependent
signaling pathways and is involved in the signal trans-
duction of ANG II-induced cardiomyocyte hypertrophy
and fibroblast hyperplasia (17). Transgenic animal
models have been generated with the aim to evaluate
the importance of the RAS in cardiac hypertrophy. A
new hypertensive mouse model lacking AG expression
in the heart presented increased cardiac weight and
collagen synthesis compared with that of the normo-
tensive control mouse (3), showing that local synthesis
of AG is involved but not essential in the development
of cardiac hypertrophy. On the other hand, isoprotere-
nol increases LV weight and ANG II concentration in
this tissue even in nephrectomized rats (34), suggest-
ing that the activation of local systems releasing ANG
Fig. 3. Tonin-specific (A) and total activities (B) in the heart struc-
tures. The activity was determined by incubating samples with
(1–14)angiotensinogen (AG), and ANG II was quantified by radioim-
munoassay. *P 
 0.05 compared with control.
Fig. 2. Expression levels of atrial natriuretic peptide (ANP) in the
LV of control (C) and Iso-treated animals determined by ribonuclease
protection assay (RPA). A: graphic representation of the ANP-to--
actin mRNA ratio; B: radioactive image of the polyacrylamide gel
electrophoresis. *P 
 0.05 compared with control.
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II in the heart may contribute to isoproterenol-induced
hypertrophy. The abnormal accumulation of fibrillar
collagen in the extracellular space of the hypertrophied
heart was already observed by Weber and colleagues
(47). The main site of AG synthesis in the heart is the
AT (37). After 8 days of treatment with isoproterenol,
AG mRNA levels in the heart were markedly induced
(23). We also verified that AG is present in the AT and
that its expression level in this tissue increases by
treatment with isoproterenol. In the LV, AG was de-
tected at very low levels without a significant differ-
ence after treatment. Even though renin mRNA has
been detected by others in minute amounts in the AT,
ventricles, and isolated cardiomyocytes (16, 49), we
were not able to detect it in both the AT and LV in
control or treated animals. The presence of renin in the
heart is controversial. The general consensus indicates
that renin is present in the heart in2% of the amount
synthesized in the kidney; however, it is not yet clear
whether it is locally synthesized or taken up from the
plasma. In regard to ACE, our results show that its
levels do not change in heart tissue after isoproterenol
treatment, in contrast to the data of Ocaranza and
colleagues (36). These authors observed that long-term
administration of isoproterenol in the rat induces the
Fig. 4. Expression levels of tonin determined by RPA in the AT and
LV of the Iso-treated group (ATISO and LVISO, respectively) and the
AT, LV, and submandibular gland (Sg) of the control group. A:
graphic representation of the tonin-to--actin mRNA ratio; B: radio-
active image of the polyacrylamide gel electrophoresis. *P 
 0.05
compared with control.
Fig. 5. Expression levels of AG determined by RPA in the AT and LV
of the Iso-treated group and the AT and LV of the control group. A:
graphic representation of the AG-to--actin mRNA ratio; B: radioac-
tive image of the polyacrylamide gel electrophoresis. *P 
 0.05
compared with control.
Fig. 6. Expression levels of renin determined by RPA in the AT and
LV of the Iso-treated group and the AT, LV, and kidney (K) of the
control group. A radioactive image of the polyacrylamide gel electro-
phoresis is shown.
Fig. 7. Expression levels of tonin (A) and angiotensin-converting
enzyme (ACE; B) determined by RT-PCR in the AT and LV of the
Iso-treated group and the AT and LV of the control group. *P 
 0.05
compared with control.
H2266 TONIN AND CARDIAC HYPERTROPHY
AJP-Heart Circ Physiol • VOL 284 • JUNE 2003 • www.ajpheart.org
expression of ACE, in that LV ACE activity correlated
with ACE mRNA levels and paralleled development of
LV hypertrophy. In the heart, ACE is mainly localized
on fibroblasts and in the endothelium (50), and there is
some controversy about its participation in the heart
hypertrophy. It has been suggested that increased local
ACE expression contributes to the development of
pressure overload-induced cardiac fibrosis but is not
responsible for hypertrophy in the rat (27) and that
mechanisms different from activation of the RAS may
play a decisive role in the maintenance of hypertrophy,
particularly in the model of volume hemodynamic over-
load (44). Our results show for the first time that tonin
is present in the heart. Furthermore, tonin activity and
expression in the AT were stimulated by isoproterenol
treatment. However, tonin mRNA could not be de-
tected by RPA before treatment. This could be ex-
plained by the results showing low levels of tonin-
specific activity in the tissue homogenate, which were
significantly altered only in the AT. Tonin-specific ac-
tivity in the AT increased almost 2-fold after treatment
and became 6.5- and 13-fold higher than that in the LV
and RV, respectively. Total activity in the AT increased
2.2-fold, whereas in the LV and RV the augmentation
was proportional to the mass increase. Taking into
account that the levels of tonin mRNA and activity
increased significantly in the AT after treatment, tonin
may represent one of these ANG II-releasing systems
that contributes to isoproterenol-induced hypertrophy.
Because tonin and AG are present in greater amounts
in the AT, the cardiac interstitium could probably be
the pathway by which tonin-generated ANG II can
reach the ventricles (48). Tonin in the AT can also
participate in the metabolism of other peptides such as
substance P and in the processing of ANP. Tonin can
cleave synthetic peptides that reproduce the sequence
of rat pro-ANP in the region of the activation site (32).
So far, no enzyme(s) that could process pro-ANP in vivo
has been clearly identified. As ANP is stored as a large
protein precursor in cardiac myocytes, tonin may be
involved in the activation of this peptide in vivo.
In conclusion, our data suggest that tonin may be an
important pathway for the generation of ANG II in the
AT and ventricles, causing a new dynamic in heart
function, with an increase in positive inotropic and
chronotropic effects and remodeling of the myocar-
dium. Therefore, the generation of drugs aiming to
modulate tonin activity may be used as a new therapy
to treat cardiovascular diseases. ACE inhibitors are
important tools for reversing cardiac hypertrophy;
however, a question that arises from these data is: how
altered are the expression levels of tonin in cardiac
tissue after treatment with these drugs?
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